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Abstract
 
CD4 T cells activated in vitro by anti-CD3/28–coated beads are resistant to infection by CC
chemokine receptor 5 (CCR5)-dependent HIV-1 isolates. In vivo, antigen-presenting cells
(APCs) activate CD4 T cells in part by signaling through the T cell receptor and CD28, yet
cells stimulated in this manner are susceptible to HIV-1 infection. We show that cytotoxic T
lymphocyte antigen 4 (CTLA-4) engagement counteracts the CD28 antiviral effects, and that
the ratio of CTLA-4 to CD28 engagement determines the susceptibility of HIV-1 infection.
Furthermore, unopposed CTLA-4 signaling provided by CD28 blockade promotes vigorous
HIV-1 replication, despite minimal T cell proliferation. Finally, CTLA-4 antibodies decrease
the susceptibility of antigen-activated CD4 T cells to HIV, suggesting a potential approach to
prevent or limit viral spread in HIV-1–infected individuals.
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Introduction
 
Cell activation is required for productive HIV-1 infection
(1, 2). HIV-1 can infect resting CD4 T cells, but the infec-
tion is aborted unless the cell reaches the G1b stage of the
cell cycle within hours after infection (3). The necessity for
T cell activation reflects, at least in part, a requirement for
induction of nuclear factor of activated T cells (NFATc)
(4). In vivo, optimal T cell activation occurs when an APC
engages the TCR–CD3 complex and a costimulatory mol-
ecule on the same cell (5). CD28, the most potent costim-
ulator, is highly expressed on resting T cells and upon en-
gaging either B7.1 or B7.2 on the surface of APCs, it
activates multiple pathways involved in cell growth and ef-
fector functions (6, 7).
Cells stimulated in vitro by polystyrene beads coated
with anti-CD3 and anti-CD28 antibodies (CD3/28 beads)
undergo long-term polyclonal expansion and are resistant
to infection by HIV-1 isolates that use the 
 
b
 
-chemokine
receptor, CC chemokine receptor 5 (CCR5)
 
1
 
, as a core-
ceptor (R5 isolates) (8). R5 isolates are implicated in trans-
mission and are found during the early stages of HIV infec-
tion (9). CD28 costimulation induces the downregulation
of CCR5 mRNA levels as well as CCR5 surface expres-
sion, and enhances production of the 
 
b
 
-chemokines regu-
lated on activation, normal T cell expressed and secreted
protein (RANTES), macrophage inflammatory protein
(MIP)-1
 
a
 
, and MIP-1
 
b
 
 (10–13). These 
 
b
 
-chemokines are
the natural ligands for CCR5, and their secretion can in-
hibit entry of R5 viruses (14).
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Abbreviations used in this paper:
 
 allo, allogeneic; CCR5, CC chemokine re-
ceptor 5; CTLA-4, CTL antigen 4; CXCR4, CXC chemokine receptor
4; DC, dendritic cell; RANTES, regulated on activation, normal T cell
expressed and secreted; MIP, macrophage inflammatory protein; RT, re-
verse transcriptase; TCID
 
50
 
, half-maximal tissue culture infectious dose;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TT, tetanus toxoid. 
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CTLA-4 Blocks CD28 Antiviral Effect
 
While cells stimulated by CD3/28 beads in vitro are re-
sistant to infection with R5 HIV-1 isolates, CD4 T cells
stimulated in vivo by APCs are the primary targets of HIV
infection. We hypothesized that interplay between other
costimulatory molecules may oppose or alter the antiviral
effects of CD28 costimulation. CTL antigen 4 (CTLA-4), a
costimulatory molecule structurally related to CD28, is able
to bind members of the B7 family with a higher affinity
than CD28 and unlike CD28, is not detectable on the sur-
face of resting cells (15–17). CTLA-4 engagement leads to
decreased cell activation and appears to function as an im-
mune attenuator (18). A genetic approach involving germ-
line disruption of CTLA-4 expression revealed a striking
inhibitory role of CTLA-4 function on proliferation of ma-
ture T cells, particularly cells of the CD4 lineage (19–21).
Another approach involved stimulating cells in the pres-
ence of anti–CTLA-4 antibodies. Anti–CTLA-4 antibodies
and Fab fragments augment T cell proliferation under cer-
tain conditions, suggesting that blocking CTLA-4–B7
interactions prevents the delivery of a negative signal (22–
24). In this report, we find that CTLA-4 engagement ren-
ders cells highly susceptible to HIV infection. CTLA-4 li-
gation blocks both the CD28-mediated downregulation of
CCR5 expression and upregulation of 
 
b
 
-chemokine ex-
pression. These results show that dynamic interactions be-
tween CD28, CTLA-4, and their ligands govern the out-
come infection of CD4 T cells by HIV-1.
 
Materials and Methods
 
Cell Separation and Generation of Dendritic Cells. 
 
Peripheral
blood lymphocytes were isolated over Percoll (Amersham Phar-
macia Biotech) gradient centrifugation from leukopacks obtained
by apheresis of healthy donors. CD28
 
1
 
CD4
 
1
 
 T cells were puri-
fied by negative selection using magnetic beads (Dynal) as de-
scribed previously (25) and were routinely 
 
.
 
98% CD3
 
1
 
, 
 
.
 
98%
CD28
 
1
 
, and 
 
,
 
3% CD8
 
1
 
 as judged by flow cytometry. To gen-
erate blood-derived dendritic cells (DCs), monocytes were iso-
lated by Percoll gradient centrifugation and further enriched by
gravity sedimentation. The monocytes differentiated into DCs af-
ter culture with IL-4 (a gift of Schering-Plough, Levallois-Perret,
France) and GM-CSF (Immunex) (26). If the DCs were to be
used for antigen-specific stimulation, tetanus toxoid (TT; Lederle
Laboratories) was added before maturation. The DCs were then
matured in the presence of TNF-
 
a
 
 (R&D Systems) for an addi-
tional 4 d before use.
 
CD4 T Cell Stimulation Using Magnetic Beads. 
 
Cells were
stimulated with magnetic beads coated with a constant amount of
anti-CD3 (humanized OKT3; a gift of Dr. Jeffrey Bluestone,
University of Chicago, Chicago, IL) and various amounts (indi-
cated in the text) of anti-CD28 (clone 9.3) (27), anti-MHC class I
(W6/32; American Tissue Type Collection), or anti–CTLA-4
(3D6) (28) as described previously (8, 29). To verify the amounts
of antibody loaded, the beads were stained with pretitered
amounts of goat anti–mouse IgG2a-PE, IgG2b-PE, or IgG1-PE
(Southern Biotechnology Associates, Inc.). This approach was
not possible with the MHC class I (W6.32)-coated beads, as the
isotype of this antibody and CD28 mAbs were the same. Goat
anti–human IgG was used to detect the humanized OKT3 mAb.
Flow cytometry was then used to quantitate antibody bound to
 
the beads. Alternatively, cells were stimulated with 3–5 
 
m
 
g/ml
PHA (Sigma-Aldrich) and 100 U/ml IL-2 (Chiron). Cells were
cultured at 1 
 
3
 
 10
 
6
 
/ml in complete medium RPMI 1640 (Bio-
Whittaker) supplemented with 10% fetal bovine serum (Hy-
clone), 2 mM 
 
l
 
-glutamine (BioWhittaker), and 20 mM Hepes
(BioWhittaker). Cell volume and cell number were monitored
on a Coulter counter (model ZM; Beckman Coulter) and
Channelyzer (model 256; Beckman Coulter). The culture me-
dium was renewed at 2–3-d intervals, and the T cells were main-
tained at a concentration of 1–2 
 
3
 
 10
 
6
 
 cells/ml.
 
CD4 T Cell Stimulation by DCs.
 
Allogeneic MLR was per-
formed by mixing 10
 
6
 
 freshly isolated CD4 T cells with alloge-
neic DCs irradiated at 3,000 rads from a 
 
137
 
Cs source at a 20:1
ratio in AIM V (GIBCO BRL) supplemented with 3% heat-inac-
tivated human serum (NorML Cera-Plus
 
®
 
; North American Bio-
logical, Inc.). After 3 d of culture, the medium was supplemented
with 100 U/ml of IL-2 and this level was maintained throughout
the experiment.
TT-specific CD4 T cell lines were generated by repeated stim-
ulations (three to seven) of CD4 T cells with autologous TT-
pulsed DCs. For each restimulation, TT-specific CD4 T cells
were cultured at 10
 
6
 
 cells per well in 24-well plates in AIM V
supplemented with 3% heat-inactivated human serum with autol-
ogous irradiated TT-pulsed DCs at a 40:1 ratio for 6 d. 100 U/ml
of rIL-2 was added after 3 d of culture and IL-2 was replenished
throughout the experiment. The culture medium was renewed at
2–3-d intervals, and the T cells were maintained at a concentra-
tion of 1–2 
 
3
 
 10
 
6
 
 cells/ml.
 
Generation and Use of Fab Fragments. 
 
Fab of anti-CD28 (9.3)
and F(ab
 
9
 
)
 
2
 
 fragments of anti–CTLA-4 (CT26) were prepared us-
ing ImmunoPure IgG1 Fab and F(ab
 
9
 
)
 
2
 
 Preparation kit according
to the manufacturer’s instructions (Pierce Chemical Co.). In pre-
liminary experiments, we found that Fab fragments of the
CTLA-4 mAb did not retain binding activity, whereas full activ-
ity was retained with F(ab
 
9
 
)
 
2
 
 fragments of the CTLA-4 mAb.
Where indicated, these fragments were added to CD4 T cells 1 h
before stimulation and maintained at 25 
 
m
 
g/ml for the first 6 d of
culture.
 
Flow Cytofluorometric Analysis. 
 
10
 
6
 
 CD4 T cells were stained
with anti-CCR5–PE, anti-CXC chemokine receptor 4 (CXCR4)–
PE, or an equivalent amount of an isotype control (BD PharMin-
gen) for 30 min at 4
 
8
 
C. After washing in PBS with 0.01% sodium
azide and 0.05% BSA (wash buffer), stained cells were analyzed
immediately by flow cytometry on a FACScan™ (Becton Dick-
inson) after gating on live lymphocytes based on a standard light
scatter histogram (integral forward scatter versus log 90
 
8
 
). Data
was analyzed using WinMDI software (J. Trotter, The Scripps
Research Institute, La Jolla, CA). Markers were set so that the
isotype control would be 2% positive.
 
Acute Infection and PCR/Liquid Hybridization Procedures.
 
Resting CD4 T cells as well as cells stimulated for 6 d were in-
fected with either HIV-1
 
US-1
 
 (30) or HIV-1
 
NL4-3
 
 (31) as described
previously (10, 12). In brief, for each infection, 5 
 
3
 
 10
 
6
 
 cells
were resuspended in 400 
 
m
 
l of 50% conditioned medium con-
taining 1–3 
 
3
 
 10
 
5
 
 half-maximal tissue culture infectious doses
(TCID
 
50
 
) of HIV-1. The cells were incubated at 37
 
8
 
C for 2 h,
washed three times in complete medium to remove excess virus,
and resuspended in 50% conditioned medium at 10
 
6
 
/ml. Anti-
body-coated beads were removed immediately before the start of
the infection. In experiments in which resting CD4 T cells were
infected, the cells were stimulated immediately after infection. In
cases where Fab fragments were added, the cells were infected
first, then incubated with the appropriate Fab fragment for 1 h af- 
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ter which they were stimulated. At designated time points, 10
 
6
 
cells were pelleted by centrifugation and frozen at –70
 
8
 
C. The
cell pellets were lysed, amplified by PCR using HIV 
 
gag
 
-specific
primers, and the amplified sequences were detected by hybridiza-
tion to a radiolabeled internal probe (32, 33). The hybridized
products were resolved by electrophoresis on 10% polyacryl-
amide gels, exposed to a PhosphorImager
 
®
 
 screen overnight, and
developed on PhosphorImager
 
®
 
 445 SI (Molecular Dynamics).
To ensure that the reactions were performed within the linear
range of the assay, log increments of HIV 
 
gag
 
 plasmid standards
were amplified at the same time (not shown). Human 
 
b
 
-globin
sequences were PCR amplified to assure that equivalent levels of
input DNA were present in each PCR reaction (32, 33). Data
were analyzed using ImageQUANT™ software (Molecular Dy-
namics).
 
Chemokine Measurements. 
 
Levels of MIP-1
 
a
 
, MIP-1
 
b
 
, and
RANTES in cell supernatants were measured using ELISA kits
from R&D Systems according to the manufacturer’s instructions.
 
Chemokine Receptor Reverse Transcription PCR Assay. 
 
Total
RNA was isolated from cells using RNA STAT-60 (Tel-Test,
Inc.) and cDNA was synthesized using the StrataScript reverse
transcriptase (RT)-PCR kit (Stratagene). cDNA products were
diluted in H
 
2
 
O to predetermined optimal concentrations (1:3 for
CCR5, 1:3,000 for glyceraldehyde 3-phosphate dehydrogenase
gene [GAPDH]) and amplified using the following program:
95
 
8
 
C, 30 s; 55
 
8
 
C, 30 s; and 72
 
8
 
C, 90 s (25 cycles) as described
previously (34). For CCR5-specific amplifications, the following
primers were used: CCR5-42 (5
 
9
 
-GGG TGG AAC AAG ATG
GAT TAT CAA GTG TCA-3
 
9
 
) and CCR5-640 (5
 
9
 
-ATG TCT
GGA AAT TCT TCC AGA ATT GAT ACT-3
 
9
 
). For GAPDH-
specific amplifications, the following primers were used: GAPDH-
61 (5
 
9
 
-ATG GGG AAG GTG AAG GTC GGA GTC AAC
GGA-3
 
9
 
) and GAPDH-433 (5
 
9
 
-AGG GGG CAG AGA TGA
TGA CCC TTT TGG CTC-3
 
9
 
). A portion of the PCR reaction
was hybridized as described (34) with end-labeled oligonucle-
otide probes specific for CCR5 (5
 
9
 
-GGG CTC CGA TGT ATA
ATA ATT GAT GTC ATA-3
 
9
 
) or GAPDH (5
 
9
 
-TCG CTC
CTG GAA GAT GGT GAT GGG ATT TCC-3
 
9
 
). The hybrid-
ized products were separated on 6% polyacrylamide gels, exposed
to PhosphorImager
 
®
 
 screens overnight and developed on a Phos-
phorImager
 
®
 
 445 SI (Molecular Dynamics). Figures were gener-
ated using ImageQUANT™ software (Molecular Dynamics).
 
Results
 
CTLA-4 Engagement Prevents the CD28-mediated Down-
regulation of CCR5 Expression.
 
The interplay between the
costimulatory effects of CD28 and CTLA-4 and resulting
susceptibility to HIV infection was examined initially by
varying the ratio of the costimulatory signals delivered. We
prepared immunobeads containing a constant level of 
 
anti-
 
CD3 combined with varying ratios of 
 
anti-
 
CD28 and 
 
anti–
 
CTLA-4 (29). Corresponding control sets of immunobeads
were prepared containing 
 
anti-
 
CD3 combined with varying
ratios of 
 
anti-
 
CD28 and 
 
anti-
 
MHC class I (
 
anti–
 
MHC I).
To simplify nomenclature, beads containing 
 
anti-
 
CD3 cou-
pled with one part 
 
anti-
 
CD28 and nine parts 
 
anti–
 
CTLA-4
are referred to as 1:9 CD28/CTLA-4. Similarly, beads that
comprised three parts 
 
anti-
 
CD28 and seven parts 
 
anti–
 
MHC I and a constant amount of 
 
anti-
 
CD3, are termed 3:7
CD28/MHC I. Freshly isolated CD4 T cells were stimu-
lated with immunobeads for 3 d, after which the beads
were removed and the cells were examined for CCR5 ex-
pression, 
 
b
 
-chemokine expression, and susceptibility to in-
fection with R5 isolates of HIV-1.
Resting CD4 T cells are characterized by a small cell
volume and moderate levels of CCR5 surface expression
(13, 35). As we demonstrated previously, stimulation with
1:9 CD28/CTLA-4 beads induced little or no cell activa-
tion, as judged by the maintenance of small resting volumes
and minimal cell proliferation (29). In contrast, cells treated
with all other combinations of beads (Fig. 1) were strongly
activated, as indicated by marked increases in cell volume
and induction of cell proliferation. Since HIV-1 infection is
influenced by the activation state of the T cell (36, 37), we
focused on studying the effects of CTLA-4 ligation on
Figure 1. Cell growth (A) and cell volume (B) changes after stimula-
tion with polystyrene beads containing varying ratios of CD28 to CTLA-4.
Freshly isolated CD4 T cells were stimulated with immunobeads contain-
ing different ratios of anti-CD28 to anti–CTLA-4 or anti–MHC class I at
a fixed amount of anti-CD3. Cell volume and growth kinetics were mea-
sured every 3 d. Data shown are representative of four experiments. d, 1:9
CD28/MHC I; s, 1:9 CD28/CTLA-4; ., 3:7 CD28/MHC I; ,, 3:7
CD28/CTLA-4; j, 5:5 CD28/MHC I; h, 5:5 CD28/CTLA-4; r, 7:3
CD28/MHC I; and e, 7:3 CD28/CTLA-4. fL, femtoliters.1990 CTLA-4 Blocks CD28 Antiviral Effect
HIV-1 infection by using cells activated with 3:7 CD28/
CTLA-4 beads, as their matched controls stimulated with
3:7 CD28/MHC I beads had similar growth kinetics.
We next examined the effects of CD3, CD28, and
CTLA-4 ligation on the induction of CCR5 expression.
CCR5 expression in CD4 cells stimulated with 3:7 CD28/
MHC I beads was strongly downregulated to undetectable
levels, suggesting that this level of CD28 occupancy was
sufficient to mediate the CD28 antiviral effect (Fig. 2). In
contrast, a substantial fraction (63%) of CD4 cells stimu-
lated with 3:7 CD28/CTLA-4 beads expressed high levels
of CCR5. When cells were stimulated with beads contain-
ing higher ratios of anti-CD28 to anti–CTLA-4, the ability
of CTLA-4 costimulation to maintain surface CCR5 ex-
pression diminished (data not shown). Thus, these results
suggest that the ratio between signals delivered by CD28
and CTLA-4 in the context of CD3 ligation governs sur-
face CCR5 expression.
Previously, we have shown that optimal levels of CD28
costimulation leads to downregulation of steady state
CCR5 RNA levels (12, 13). Furthermore, CD3/28 bead–
stimulated cells are unable to transcribe heterologous genes
linked to the CCR5 promoter (11). These observations
suggested that CTLA-4 ligation may interfere with the
CD28-mediated downregulation of CCR5 transcript lev-
els. Therefore, we isolated RNA from both 3:7 CD28/
MHC I bead– and 3:7 CD28/CTLA-4 bead–stimulated
cells and used a semiquantitative RT-PCR method to ex-
amine CCR5 mRNA levels (Fig. 2 B). As expected in cells
stimulated by 3:7 CD28/MHC I beads, only trace levels of
CCR5 could be detected. In contrast, cells stimulated by
3:7 CD28/CTLA-4 had high levels of CCR5 RNA, sug-
gesting that CTLA-4 ligation blocks the CD3/CD28-medi-
ated downregulation of CCR5 transcript levels.
CTLA-4 Costimulation Exerts Only Modest Effects on b-Che-
mokine Production.  The CD28 antiviral effect com-
prises at least two components: downregulation of CCR5
expression and enhancement of b-chemokine production
(10, 12, 13). Table I shows the levels of b-chemokine se-
cretion by CD4 cells after 3 d of stimulation with the
CD28/CTLA-4 or CD28/MHC I beads. In all three do-
nors, CD4 T cell stimulation with either CD28/MHC I or
CD28/CTLA-4 beads resulted in high levels of b-che-
mokine production. In most cases, less than a twofold
difference was observed between the CD28/MHC I– and
CD28/CTLA-4–stimulated cells, suggesting that CD28/
CTLA-4 did not markedly alter b-chemokine production.
The notable exception is CD28/MHC I stimulated cells,
which produced z10-fold more MIP-1a than the CTLA-
4–stimulated cells in two of the three donors. At this point,
it is unclear whether or not CTLA-4 has a direct role in
MIP-1a production. Thus, in contrast to CCR5 downreg-
ulation, b-chemokine production appeared to be relatively
insensitive to CTLA-4 engagement, suggesting that differ-
ent costimulatory pathways or different thresholds of CD28
signaling are required to regulate CCR5 expression and
b-chemokine production.
Figure 2. CCR5 levels in CD4 T cells stimulated with anti-CD3/28/
CTLA-4 immunobeads. CD4 T cells were isolated and stimulated with
beads containing a 3:7 ratio of anti-CD28 to anti–CTLA-4 or anti–MHC
class I beads for 6 d. (A) Cytofluorometric analysis of CCR5 (red) or iso-
type control (open) fluorescence. Values of 2% or less are considered back-
ground. (B) RT-PCR analysis of CCR5 mRNA levels. RNA was isolated
from CD4 T cells stimulated with 3:7 CD28/CTLA-4 and 3:7 CD28/
MHC I beads, and cDNA was synthesized and diluted to the optimal level
(1:3 for CCR5 and 1:3,000 for GAPDH). 2.5, 5, or 10 ml of the RT
product was used in the subsequent PCR and liquid hybridization reaction
to demonstrate that the assay was performed within the linear response
range. NO, the amplification of a cDNA reaction in a sample from which
the RT was omitted. Data shown are representative of four experiments.
Table I. CD4 T Cell b-Chemokine Secretion after Stimulation 
with Anti-CD3/28/CTLA-4 Beads
RANTES MIP-1a MIP-1b
ng/ml ng/ml ng/ml
Donor 1 CD28/CTLA-4 1 23 107
CD28/MHC I 3 195 145
Donor 2 CD28/CTLA-4 8 54 39
CD28/MHC I 11 93 66
Donor 3 CD28/CTLA-4 6 15 43
CD28/MHC I 7 160 97
CD4 T cells were purified and stimulated with immunobeads coated
with a constant level of anti-CD3 and three parts anti-CD28 with either
seven parts anti–CTLA-4 or anti–MHC I for 3 d as described in
Materials and Methods. Supernatants were collected and b-chemokine
levels were measured by ELISA.1991 Riley et al.
CTLA-4 Ligation Permits R5 Infection.  Our data sug-
gest that CCR5 expression, and hence the balance of
CD28 to CTLA-4 signaling, governs susceptibility to R5
infection. We tested this hypothesis by first stimulating
CD4 T cells with 3:7 CD28/CTLA-4 or 3:7 CD28/MHC
I beads for 3 d followed by infection with an R5 virus. Fig.
3 shows the level of HIV-1 gag DNA present in the in-
fected cells and the amount of p24Gag antigen produced by
the cells after infection. We found that 3:7 CD28/CTLA-
4–stimulated cells were highly susceptible to R5 infection,
as high levels of HIV gag DNA and p24 antigen were ob-
served. As a reference, CD4 T cells stimulated with PHA/
IL-2 were also infected and similar values were obtained
demonstrating the high susceptibility of CD4 cells stimu-
lated with 3:7 CD28/CTLA-4 to R5 infection. In contrast,
3:7 CD28/MHC I–stimulated cells remained resistant to
R5 infection, suggesting that without CTLA-4 engage-
ment this level of CD28 costimulation is able to prevent
R5 infection (8, 11, 12).
Costimulation Modifies Susceptibility of PHA-activated T Cells
to HIV-1 Infection.  To generalize the previous results ob-
tained with a bead-based system of T cell activation, we car-
ried out experiments with PHA-activated T cells to deter-
mine if CTLA-4 has a similar role in a more widely studied
model of HIV infection. CD8 cell–depleted PBMCs were
infected with R5 HIV-1, and then activated with PHA in
the presence of soluble CD28 and CTLA-4 antibodies (Fig.
4). We have previously shown that the addition of CD28
Fab fragments does not activate T cells as assessed by IL-2
production and proliferation (38). A surprising augmenta-
tion of HIV replication was observed after PHA activation
in the presence of CD28 blockade despite decreased T cell
proliferation (data not shown). Dose-dependent increases in
HIV infection were not observed in cells incubated in
higher concentrations (.1 mg/ml) of CD28 Fabs. This may
be due to the overriding deleterious effects of minimal cell
activation. In contrast, a striking dose-dependent inhibition
of HIV replication was induced when CTLA-4 antibodies
were included in the culture of PHA-activated T cells (Fig.
4) in spite of increased cell proliferation (data not shown).
Thus, HIV R5 replication was increased under conditions
that promote CTLA-4 ligation and inhibited under condi-
tions with enhanced CD28 signaling.
Costimulation Modifies Susceptibility of Antigen-specific Cell
Lines to HIV-1 Infection. In vivo, T cell activation is regu-
lated through interactions with APCs. The CD80 (B7.1)
and CD86 (B7.2) ligands on the surface of the APCs are
able to bind and compete for binding to CD28 and CTLA-4
on the surface of T cells. In the next series of experi-
ments, we examined whether antigen-specific CD4 T cells
activated by autologous, antigen-loaded DCs were suscep-
tible to HIV-1 infection. First, we generated several TT-
specific CD4 T cell lines. In preliminary studies, we found
that the TT lines were dependent on costimulation, as
blockade with anti-B7 antibodies or CTLA4Ig prevented
the stimulatory effects of antigen-pulsed DCs, consistent
with previous data with tetanus-specific lines (39). These
cell lines had stimulation indices ranging from 50 to 100,
indicating a high degree of TT specificity (data not shown).
The antigen-specific cells were stimulated for 6 d with ei-
ther TT-loaded DCs or with CD3/28 beads. After stimula-
tion, the cells were infected with either an R5 or X4 isolate
of HIV-1. gag DNA and p24Gag antigen were measured
(Fig. 5). Consistent with our previous reports, which used
polyclonal, freshly isolated CD4 T cells (8, 12, 13), anti-
gen-specific cells stimulated by CD3/28 beads remained
Figure 3. CTLA-4 ligation permits HIV-1 infection of CD3/28 bead–
stimulated cells. CD4 T cells were stimulated as described in the legend to
Fig. 1 for 3 d and infected with the R5 isolates as described in Materials
and Methods. Samples were taken at t 5 0, 2, 72, and 144 h after infec-
tion and cell pellets were analyzed for gag DNA by a quantitative PCR as-
say using liquid hybridization. p24 (in ng/ml) was measured in culture su-
pernatants at 144 h after infection. Data shown are representative of three
experiments.
Figure 4. CD28 or CTLA-4 antibody fragments can modulate the sus-
ceptibility of PHA-stimulated T cells to R5 infection. Freshly isolated
CD8-depleted PBMCs were infected with HIVUS-1 (R5) and stimulated
with PHA alone or PHA in the presence of 0.1, 1, 3, and 10 mg/ml of
anti-CD28 Fab, or PHA in the presence of 0.1, 1, and 10 mg/ml of anti–
CTLA-4 F(ab9)2 fragments. p24 (in ng/ml) was measured in culture su-
pernatants collected at 6 d after infection. Data are representative of three
experiments using two different donors.1992 CTLA-4 Blocks CD28 Antiviral Effect
susceptible to infection with X4 isolates while they were
refractory to infection with R5 HIV isolates (Fig. 5). In
contrast, when antigen-specific cells were stimulated by
TT-loaded DCs, they were susceptible to both R5 and X4
strains of HIV-1, in agreement with previous studies (40,
41). X4 isolates use the coreceptor CXCR4 (42), and
typically are not detected until the later stages of HIV-1
disease (9).
We next used flow cytometric analysis to determine the
status of CD4 T cell HIV-1 coreceptor expression after
stimulation with antigen or anti-CD3/28. The coreceptor
surface expression correlated with the infection data: anti-
gen-mediated stimulation resulted in increases in CCR5
expression, whereas cells given CD3/28 bead stimulation
had no detectable CCR5 expression (Fig. 5 B). In contrast,
both antigen and CD3/28 stimulation increased CXCR4
expression. This latter finding is consistent with our previ-
ous reports, which showed increases in CXCR4 expres-
sion in T cells after CD3/CD28 stimulation (12). In the
experiments with tetanus-specific CD4 cell lines, we noted
a major difference (.1,000-fold) in the level of b-che-
mokines secreted after antigen and CD3/28 bead stimu-
lation, with nearly undetectable levels found after antigen
stimulation (data not shown). Taken together, high CCR5
levels and low b-chemokine production explain the high
levels of virus replication seen in the antigen-specific cells.
Thus, despite B7/CD28 interactions, the antigen-specific
cells are highly susceptible to R5 isolates, consistent with
the notion that other costimulatory molecules such as
CTLA-4 may be interfering with the CD28-mediated an-
tiviral effects.
Modulation of HIV Infection After Antigen Stimulation with
CTLA-4 and CD28 Antibody Fragments.  To ascertain
whether or not the susceptibility of antigen-activated cells
could be modulated by altering the levels of CD28 and
CTLA-4 costimulation, we generated Fab fragments to
CD28 and F(ab9)2 fragments to CTLA-4. As with the PHA
experiment shown in Fig. 4, we reasoned that these frag-
ments, by virtue of their ability to bind but not cross-link
their target molecules by Fc receptors, could promote the
use of one costimulatory pathway at the expense of the
other. Fab fragments of anti-CD28 mAb 9.3 have been
shown to block allogeneic MLR reactions (43) and intact
and Fab fragments of anti–CTLA-4 mAbs have been
shown to enhance MLRs and T cell clonal expansion (23,
44). Fab fragments to CD28 would be predicted to steri-
cally prevent B7–CD28 interaction, favoring B7–CTLA-4
interactions and thus making antigen-activated cells more
susceptible to R5 infection.
The ability of Fab fragments to alter the susceptibility of
CD4 T cells to HIV infection was first tested by infecting
resting TT-specific clones with both R5 and X4 strains of
HIV-1. The infection was allowed to proceed for 2 h, after
which unbound virus was washed out. The CD4 T cells
were then stimulated immediately with autologous, TT-
pulsed DCs, either in the presence or absence of anti-
CD28 or anti–CTLA-4 fragments. As a control, infected
cells were also stimulated with CD3/28 beads. Superna-
tants were removed from the cultures 6 d after infection
and analyzed for the presence of HIV p24Gag antigen (Fig.
6). In CD4 T cells first infected with an R5 strain and then
stimulated with CD3/28 beads, p24Gag antigen was unde-
tectable (Fig. 6 A). It is likely that the CD28-mediated
downregulation of CCR5 and upregulation of b-chemo-
kine production prevented viral spread, similar to observa-
tions made when CD4 T cells from HIV-infected individ-
uals were stimulated in vitro with CD3/28 beads (8). In
contrast, a robust infection ensued in antigen-stimulated
CD4 T cells stimulated with DCs. Stimulation with DCs in
the presence of anti–CTLA-4 fragments rendered these
cells much less permissive to a spreading HIV-1 infection
(sevenfold reduction in p24), whereas stimulation of CD4
T cells by DCs in the presence of anti-CD28 Fab fragments
markedly increased the amount of p24 produced (Fig. 6 A).
These observations suggested that the anti–CTLA-4 frag-
ments impeded with B7–CTLA-4 interactions, promoting
stronger B7–CD28 signaling, whereas anti-CD28 fragments
interfered with B7–CD28 interactions, thus strengthening
B7–CTLA-4 interactions.
Figure 5. Antigen-specific cell lines are susceptible to R5 infection
when stimulated with autologous DCs. (A) TT-specific CD4 T cells were
stimulated with TT-loaded autologous DCs for 6 d and infected with ei-
ther HIVUS-1(R5) or HIVNL4-3 (X4) as described in Materials and Meth-
ods. Samples were taken at t 5 0, 2, 72, and 144 h after infection and cell
pellets were analyzed for gag DNA by a quantitative PCR assay using liq-
uid hybridization. p24 (in ng/ml) was measured in culture supernatants at
144 h after infection. (B) Cytofluorometric analysis of CCR5 (green his-
togram), CXCR4 (dark open histogram), or isotype control (light open
histogram) of the cells described above before infection. Data are repre-
sentative of three independent experiments.1993 Riley et al.
Further support for the role of CTLA-4 in regulating
CD4 T cell susceptibility to R5 infection was gathered by
examining CCR5 expression in the treated cells. As pre-
dicted, treatment with anti–CTLA-4 fragments resulted in
a decrease in CCR5-expressing cells. 30% of the CD4 T
cells stimulated with DCs plus TT expressed CCR5 com-
pared with 21% when the anti–CTLA-4 F(ab9)2 were
added (data not shown). In contrast, treatment with anti-
CD28 Fab fragments resulted in an increase in the number
of cells expressing CCR5 (52%), suggesting that CCR5
levels are predictive of the level of HIV-1 production in
this model system.
Manipulations of costimulatory molecule interactions in
cells infected with an X4 virus isolate produced strikingly
different results (Fig. 6 B). Unlike CCR5, CXCR4 expres-
sion (30 6 5%) remained unchanged by the different meth-
ods of activation. Nonetheless, a marked decrease in p24Gag
production in antigen-specific stimulated cells in the pres-
ence of anti-CD28 Fabs was observed, suggesting that the
reduced level of cell activation caused by the anti-CD28
Fabs is inhibiting viral replication. This result underscores
the differences seen in Fig. 6 A and implies that even larger
differences might be observed if similar levels of cell activa-
tion were achieved. Likewise, treatment with anti–CTLA-4
F(ab9)2 slightly increased X4 replication rather than dimin-
ishing it as seen with an R5 virus.
Modulation of HIV Infection After Allogeneic Stimulation with
CTLA-4 and CD28 Antibody Fragments.  A potential lim-
itation of data obtained from antigen-specific cell lines is
that these cells have been cultured ex vivo. They have un-
dergone multiple cycles of stimulation and cell division and
thus are reasonable models for recall responses, but may not
adequately reflect T cell behavior in vivo for primary re-
sponses to antigen. To address this concern, we examined
CD28/CTLA-4 modulation and susceptibility to HIV in-
fection in an MLR involving allogeneic (allo) DCs mixed
with fresh primary CD4 T cells. Previous studies found that
allostimulation has dichotomous effects on replication of
R5 strains of HIV-1 in that it activates HIV expression in
previously infected cells but inhibits HIV entry by the pro-
duction of b-chemokines (45). Purified resting CD4 T
cells were infected with an R5 HIV-1 isolate and then
stimulated with CD3/28 beads, allo DCs, or allo DCs plus
anti–CTLA-4 or anti-CD28 antibody fragments. p24Gag
analysis was performed on day 9 after infection supernatant.
Figure 6. Anti-CD28 Fab and anti–CTLA-4
F(ab9)2 fragments can modulate the susceptibility of
antigen-stimulated CD4 T cells to HIV-1 infec-
tion. (A) Before restimulation, TT-specific CD4 T
cells were infected with an R5 strain (HIVUS-1) and
stimulated with antigen-loaded DCs in the pres-
ence or absence of 25 mg/ml of anti-CD28 or anti–
CTLA-4 fragments. Alternately infected cells were
stimulated with CD3/28 beads. Supernatant p24
(in ng/ml) was measured 6 d after infection. (B)
Cells were stimulated as in A and infected with X4
isolate HIV-1NL4-3. Data shown are representative
of two experiments.
Figure 7. CD28 or CTLA-4 antibody fragments can modulate the sus-
ceptibility of MLR-stimulated CD4 T cells to R5 infection. Freshly iso-
lated CD4 T cells were infected with HIVUS-1 (R5) and stimulated with
allo DCs, allo DCs in the presence of either 25 mg/ml of anti–CD28 Fab
or 25 mg/ml anti-CTLA-4 F(ab9)2 fragments, or CD3/28 beads. p24 (in
ng/ml) was measured in culture supernatants collected 9 d after infection.
Data are representative of three independent experiments in which the
mean fold difference for the cultures treated with anti–CTLA-4 was 27.1 6
2.2, and the mean fold difference for culture treated with anti-CD28 frag-
ments was 14.6 6 4.3. (B) RANTES and MIP-1a levels were measured
9 d after the stimulations described in A.1994 CTLA-4 Blocks CD28 Antiviral Effect
Consistent with the data obtained from antigen-specific
cells, CD4 T cells stimulated with DCs alone were suscep-
tible to infection and those stimulated with CD3/28 beads
were resistant to infection. Moreover, addition of anti–
CTLA-4 fragments decreased viral production 5-fold,
whereas the addition of anti–CD28 Fab fragments in-
creased the amount of virus produced 18-fold (Fig. 7 A).
Thus, addition of anti-CTLA-4 and anti-CD28 fragments
to cells stimulated by allo DCs generated outcomes similar
to those observed in the antigen-specific lines.
Overall, the level of CCR5 expression in cells stimulated
by allo DCs was low (4%), and this probably contributes to
the decreased level of viral replication that occurs in cells
stimulated in this manner. Nonetheless, CCR5 expression
was consistently increased by the addition of anti-CD28
fragments (6%) and decreased by anti–CTLA-4 fragments
(2%). We also examined the levels of b-chemokines
present in the supernatant at the time of infection. Overall,
allo DC–stimulated cells produced lower levels of b-che-
mokines than CD3/28-stimulated cells. The addition of anti–
CTLA-4 Fabs to the MLR led to modest yet reproducible
increases in b-chemokine production, whereas the addition
of anti-CD28 Fabs dramatically lowered b-chemokines
levels (Fig. 7 B). These reduced levels of b-chemokine
production coupled with the increased levels of CCR5
may explain the high levels of R5 replication seen in these
cells. As with the antigen-specific cell model, infection of
the MLR in the presence of a CD28 Fab fragments using
an X4 virus led to much lower levels of virus replication
(data not shown), supporting the role of cell activation in
HIV infection and accentuating the differences seen when
an R5 virus is used.
Discussion
CD28 Antiviral Effect. These results refine a role for
CTLA-4 in HIV-1 infection. The resistance of CD3/
CD28-stimulated CD4 T cells to HIV infection contrasts
sharply with the susceptibility of CD4 T cells to HIV infec-
tion in vivo, where they are activated by APCs. A key dif-
ference between CD3/CD28 bead costimulation and anti-
gen-driven costimulation is that the APCs can also engage
CTLA-4. We have confirmed that CD4 cells activated by
DCs are highly susceptible to infection by R5 HIV-1 iso-
lates (40, 46). Furthermore, by specifically blocking B7–
CD28 interactions, we have enhanced HIV replication in
the target cells. Conversely, blocking B7–CTLA-4 interac-
tions rendered the cells resistant to HIV infection. The re-
sults were robust, as similar effects were also observed in
cells stimulated with lectins and soluble CD28 and CTLA-4
antibodies as with antigen-specific T cell activation–medi-
ated peptide–MHC complexes on DCs. Thus, our results
suggest that in vivo, the function of CTLA-4 is critical for
inducing HIV susceptibility.
Previous studies have demonstrated the importance of
costimulatory signal transduction for HIV infection of CD4
cells. Several investigators have shown that CTLA4Ig, a
soluble form of CTLA-4, can decrease or prevent HIV in-
fection of CD4 T cells. DC-mediated transmission of X4
strains to CD4 cells was increased by anti-CD28 and
blocked by CTLA4Ig (47). Haffar et al. found that infected
T cells could present alloantigen to fresh, uninfected CD4
T cells, leading to increased proliferation and virus spread
to the activated cells, and that both of these events were
blocked by CTLA4Ig (48). Mature DCs in peripheral
blood were shown to bind HIV and induce infection when
added to autologous CD4 T cells in the absence of added
stimuli, and this infection was inhibited by CTLA4Ig (40).
However, these studies did not reveal the discrete roles of
CD28 and CTLA-4, nor have they distinguished between
requirements for cellular activation and the subsequent in-
ability to sustain productive HIV infection.
The mechanism by which CD3/28 bead costimulation
regulates CCR5 and b-chemokine expression is unknown.
Moriuchi et al. used a heterologous gene reporter system to
show that CD28 costimulation inhibits transcription from
the CCR5 promoter (11). As CD28 costimulation affects
both the transcription rate and the mRNA stability of
many genes (6), it remains to be seen whether other factors
are involved in CCR5 regulation. How CTLA-4 blocks
CD28’s actions represents an even more complex question.
It is not yet known whether signaling through CTLA-4 is
essential for this effect or whether simple competition for
CD28 through limiting amounts of B7 availability is suffi-
cient for this function of CTLA-4. New insights into how
CTLA-4 may inhibit cell growth show that upon cell acti-
vation CTLA-4 engagement inhibits tyrosine phosphoryla-
tion of TCR-z (49). Currently, it is unknown whether
CTLA-4 exerts all of its mechanisms through TCR-z or
whether other targets are involved in direct signal transduc-
tion by CTLA-4. For example, it has been shown that
CTLA-4 can induce TGF-b secretion (50), and TGF-b
can increase HIV transcription (51). The present results
suggest that partial inhibition of CTLA-4 signal transduc-
tion has the potential to prevent or limit HIV-1 infection.
CD28/CTLA-4 Competition, Cell Activation, and Suscepti-
bility to HIV Infection. Our results argue that the strength
of the costimulatory signals delivered by anti-CD28 and
anti–CTLA-4 play an essential role in many cellular events,
from early activation events to susceptibility to HIV infec-
tion. By constructing artificial APCs that have anti-CD3
coupled with various ratios of anti-CD28 to anti–CTLA-4,
we have shown that different quantities of anti–CTLA-4
are required to block distinct subsets of CD28-mediated
events. These results suggest that there is a hierarchy of
events elicited by different ratios of CD28 and CTLA-4 li-
gation. For instance, a bead prepared at a 1:9 ratio of anti-
CD28/anti–CTLA-4 is required to block IL-2 production,
b-chemokine production, and cell growth. However,
these same beads are unable to prevent Bcl-XL induction in
naive T cells (29). Moreover, 1:9 anti-CD28/anti–MHC I
(i.e., anti–CTLA-4 deficient) beads, while promoting vig-
orous cell proliferation, are unable to downregulate CCR5
levels (data not shown). However, 3:7 anti-CD28/anti–
MHC I beads efficiently downregulate CCR5 expression,
suggesting that stronger CD28 signaling is required for1995 Riley et al.
CCR5 downregulation than for cell growth initiation. In
contrast, 3:7 anti-CD28/anti–CTLA-4 beads induced full
activation of T cell growth, high level CCR5 expression,
and supported vigorous HIV-1 infection. Thus, our results
suggest a hierarchy of events that is elicited by different
amounts or ratios of CD28 and CTLA-4 ligation.
In vivo, the existence of different signaling thresholds for
CD28-mediated effects may serve to limit nonspecific acti-
vation, and through Bcl-XL induction, to prevent apopto-
sis. Recently, several groups have shown that MHC class II
molecules are required for long-term CD4 cell survival (52,
53). Presumably, tonic interactions between MHC class II
molecules on APCs and the TCR complex deliver cell sur-
vival signals. These tonic interactions between MHC class
II and TCR may also include B7–CD28–CTLA-4 com-
plexes. It is likely that CTLA-4–B7 interactions would be
favored, due to the higher affinity of CTLA-4 for B7 (17).
Thus, CD28-mediated signaling would be diminished to
levels insufficient to induce proliferation but sufficient to
induce Bcl-XL expression, thereby blocking the apoptosis
cascade initiated by CD3 cross-linking.
Tonic interactions between costimulatory molecules
may have important implications for HIV-1 infection. As
APCs and T cells are in frequent contact with each other,
partial CD4 T cell activation may be common, whereas full
activation (mediated by CD28 signaling) would be a more
rare event. We have examined two instances of partially ac-
tivated CD4 cells: T cells stimulated with either PHA or
APCs in the presence of CD28 Fab fragments. In both
cases, despite low levels of cellular proliferation, these cells
were highly susceptible to HIV-1 infection presumably due
to the high levels of CCR5 expression and low levels of
b-chemokine secretion. These results were surprising and
challenge the absolute link between cellular activation, and
HIV-1 infection; however, it must be noted that limited
cellular activation is required for a productive infection.
Excess anti-CD28 Fab fragments in these models severely
inhibited cellular proliferation, and this resulted in little to
no enhancement of HIV-1 replication (Fig. 4 and data not
shown). Thus, a careful titration of anti-CD28 Fab frag-
ments was required in order to prevent CD28 from down-
regulating CCR5 levels while at the same time permitting
enough cellular activation to permit a productive infection.
These models suggest that during the short time span in
which cells are partially activated, they are highly suscepti-
ble to HIV-1 infection and this may permit HIV-1 replica-
tion to occur in the absence of full activation induced by an
immune response against a pathogen. Recently, Haase and
colleagues have demonstrated that shortly after infection,
cells with a “resting” phenotype contain a significant frac-
tion of the viral load (54). Perhaps, these highly infectable
cells are the consequence of partial activation caused by
CTLA-4 engagement.
Could Targeting CTLA-4 Limit the Spread of HIV-1 Infec-
tion? The results presented here argue that B7–CTLA-4
interactions induce an HIV-sensitive state in CD4 T cells.
Blocking this interaction may limit initial HIV-1 spread
and thus lower long-term viral load. Targeting B7–CTLA-4
interactions may also have beneficial effects beyond the ini-
tial infection stage. Using an alloantigen stimulation model,
Haffar et al. showed that CD28 expression decreases over
time in infected individuals, and that viral production in-
creases concurrently with the CD28 decrease (48). Further-
more, CTLA-4 expression on CD4 T cells in patients in-
creases over the course of HIV-1 infection (55). Taken
together with the data presented here, these studies suggest
that over time the CD4 T cells in an HIV-1–infected indi-
vidual become more susceptible to HIV-1 after B7 stimula-
tion. Thus, inhibition of B7–CTLA-4 interactions, and the
concomitant promotion of B7–CD28 interactions, may
permit enhanced immunological control of HIV-1 and
contribute to the maintenance of low viral loads. Oligonu-
cleotide-based strategies to prevent or diminish CD28 ex-
pression have demonstrated some efficacy in rodents (56).
It is possible that similar reagents could be developed to
regulate CTLA-4 expression. However, since CTLA-4 has
a role in downregulating immune responses, care must be
used to prevent potentially harmful side effects resulting
from immune hyperactivation (57).
In conclusion, we have demonstrated that susceptibility
to HIV infection is controlled by interactions between
APCs and costimulatory molecules on the CD4 T cell sur-
face. CD28- and CTLA-4–mediated signaling results in a
diametrically opposed phenotype susceptibility to R5 HIV
strains. Blocking B7-mediated ligation of CTLA-4 permits
the establishment of an HIV-resistant state, and approaches
to limit CTLA-4 function may represent a therapeutic mo-
dality for HIV infection.
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